**[342] LOGICBIO THERAPEUTICS - DEVELOPING THE GENERIDE TECHNOLOGY FOR SAFE GENE THERAPY FOR ADULT AND PEDIATRIC PATIENTS**

**adi barzel1, 1 Logicbio Therapeutics**

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

 **Investment Rational**
LogicBio Therapeutics is a gene therapy company developing viral vectors for the treatment of genetic diseases.  Our technology allowed safe lifelong therapy of several genetic diseases after a single injection to either adult or pediatric animal models.

* **Business Strategy**

LogicBio is focusing on R&D. We hope to enter clinical trials for our first indications on early 2018.

**Core Technology**

LogicBio’s “GeneRide” technology is GeneRide is AAV based promoterless gene targeting without nucleases (Barzel et al, Nature 2015). For some indications, GeneRide can thus allow safe and efficacious gene targeting in both infants and adults by greatly diminishing off-target effects while still providing therapeutic levels of expression from integration.

* **Product Profile/Pipeline**
LogicBio is developing treatments for several currently incurable genetic diseases. We hope to enter clinical trials on early 2018.
* **What's Next?**
LogicBio’s GeneRide technology has allowed for the safe and lifelong therapy of several genetic diseases after a single injection to either adult or pediatric animal models. We now wish further validate our results by extensive safety and efficacy assays in different animal models. We are enaging with the regulators and will enter into GMP vector manufacturing followed by Pharm-Tox testing with hope of initiating clinical trials on early 2018. In parallel, LogicBio is recruiting management and staff and is seeking a series A investment.